Diaminobenzidine immunohistochemistry explained

Diaminobenzidine, often shortened to DAB in laboratory reports, is a colour-producing reagent used after an antibody has attached to its target. It commonly leaves a brown deposit at the site of the detected protein, making the staining pattern visible in the prepared tissue section.

The brown signal shows where the laboratory reaction occurred; it does not independently determine whether tissue is benign or malignant. A pathologist examines which cells are stained, whether the signal lies in the nucleus, membrane or cytoplasm, and how the distribution compares with expected patterns.

Background colour, tissue preservation and control samples also affect whether a stain can be trusted. The final interpretation therefore comes from the complete slide and the wider marker panel, not simply from how dark the brown colour appears. Results may be reported with descriptive terms that vary according to the marker and the clinical question.

Read the DAB finding within the diagnosis and comment sections of the pathology report. Your clinician can explain what the tested protein represents, which cells showed the signal and whether the pattern supports classification of the tissue, selection of another test or a treatment decision.

When wording such as equivocal, weak, non-specific or inadequate appears, ask what uncertainty remains. The pathology team may examine another section, use a different detection approach, repeat a control or request more tissue. Keep the report available because the marker name and staining location are more useful for discussion than the colour description alone.

DAB is handled by laboratory staff and applied to prepared tissue rather than administered as a patient medicine. Any physical recovery concerns are generally connected to the procedure used to obtain the sample. Follow the wound-care instructions and call the clinical team for spreading redness, increasing tenderness, warmth, pus, fever or persistent bleeding.

Get urgent medical help for heavy bleeding, collapse, new severe breathlessness or another sudden, severe change after the procedure. For a result that is difficult to understand, arrange follow-up with the requesting clinician instead of trying to infer a diagnosis from the presence of brown staining.

Consider asking: Which protein was the antibody designed to detect? Which part of the cells stained? Did the control tissue perform as expected? How does this result fit with the other markers and the tissue appearance? Is the finding sufficient for planning care, or is confirmatory testing required?